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A 63-year-old physician presents for genetic counseling. He
has hypertension, well controlled with an angiotensin-
converting enzyme inhibitor, and has taken a statin for
13 years. His mother has atrial ﬁbrillation (AF), and
recent genetic testing has identiﬁed AF risk alleles placing
him at 4-fold increased risk for developing AF. He is con-
cerned that waiting until the arrhythmia develops may
expose him to thromboembolic risk and has read that
antiarrhythmic drugs and ablation are less effective in in-
dividuals with his genotype. He therefore wishes to know
whether anything can be done to prevent the development of
the arrhythmia.
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A traditional view of AF holds that the arrhythmia is a
fellow traveler to other types of heart disease, and that it is
relatively straightforward to manage. This image has been
reinforced by trials such as AFFIRM (Atrial Fibrillation
Follow-up Investigation of Rhythm Management) (1) that
demonstrated the equivalence, or superiority, of a simple
“rate control” strategy compared with attempts to restore si-
nus rhythm. The fundamental problem with this type of
comparison is that strategies to restore and maintain sinus
rhythm rely on drugs that do not target fundamental mech-
anisms, are not especially well tolerated, and have distinct,
potentially lethal, adverse side effect liabilities. There is no
doubt that there is a population of patients in whom rate
control, along with appropriate anticoagulation, provides
perfectly adequate symptom control and probably no effect
on longevity. The emerging story around AF genomics and
its implications for understanding fundamental mechanisms,
and therefore predicting and perhaps even preventing the
arrhythmia, provides one way forward in this issue.*Editorials published in the Journal of the American College of Cardiology reﬂect the
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contents of this paper to disclose.“Lone” AF is a genetic disease. In the 1930s and 1940s, it
was recognized that AF could occur in the absence of un-
derlying heart disease or other risk factors we now recognize,
such as advancing age, hypertension, diabetes, obesity, or
metabolic syndrome, and in multiple family members (2,3).
This subset then acquired the label of “lone” AF, a term that
merely betrays our ignorance of underlying mechanisms.
The last decade has seen the recognition that individuals
with lone AF, who make up 10% to 30% of a tertiary care
institution’s referral population, have a strong family history
of AF (4,5). Further, in the Framingham Heart Study,
hypertension, diabetes, and a family history of AF were
found to all independently add to risk of the arrhythmia in
an individual (6). Thus, an emerging body of evidence over
the last 10 years highlights a potential role for genetic
variation as a risk factor for AF.
Studies in both families and in large populations have
been used to identify DNA polymorphisms contributing to
AF risk. Families with multiple affected members have been
investigated by linkage analysis, candidate gene sequencing,
or other methods to identify variants that segregate with the
trait (7,8) and may therefore be causative. This approach has
been modestly successful, identifying loci and seemingly
logical variants in obvious candidate genes, such as those
encoding ion channels. Difﬁculties with this approach are
that many families are not large enough for conventional
linkage analysis, and the phenotypes can be difﬁcult to
assign: some patients may carry a risk allele but not develop
the arrhythmia (incomplete penetrance), and because AF is
so common, some patients may develop the arrhythmia
without necessarily having the risk allele in their family.
AF represents a triumph of the genome-wide association
study. AF was one of the ﬁrst complex traits successfully
investigated using the genome-wide association study
(GWAS) paradigm. In an initial GWAS reported in 2007
(9), a discovery set of only 550 Icelandic cases and 4,476
controls identiﬁed a very strong association with single
nucleotide polymorphisms (SNPs) at chromosome 4q25, and
this association was subsequently replicated in this report and
others (10) in Caucasians and in a small number of Asians.
Importantly, the cases were unselected for known risk factors
such as hypertension or diabetes; the only exclusion was
post-operative AF, and subsequent studies have identiﬁed
4q25 SNPs as risk factors in this setting as well (11). This
result suggests that the 4q25 locus predisposes to AF in some
fundamental fashion independent of other risk factors, and
the identiﬁcation of this novel association (and thus new
pathway to the arrhythmia) represents a real triumph of the
GWAS technique. Most recently, Ellinor and colleagues
(12) performed a meta-analysis and replication using over
12,000 cases and identiﬁed a total of 9 risk loci. SNPs at the
4q25 locus conferred a relative risk of 1.64 (p ¼ 1.8 10–74),
whereas values at other loci were 1.13 to 1.24; SNPs at 2 loci
were protective, with relative risks of 0.85 to 0.88.
The original 4q25 SNPs are located about 150,000 base
pairs away from PITX2, which encodes a transcription factor
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1212ﬁrst described as a modulator of pituitary development. Two
months after the original 2007 GWAS reporting risk alleles
at 4q25, a group of developmental biologists reported that
deletion of Pitx2c (a cardiac-speciﬁc isoform implicated
in early left-right differentiation in the heart) in mice
resulted in failure of formation of the pulmonary vein
myocardial sleeve, the site of origin of the abnormal
automaticity that commonly drives AF (13). Mice in which
a Pitx2 allele has been deleted display increased suscepti-
bility to AF by programmed stimulation and up-regulation
of “pro-ﬁbrillatory genes,” including those in which rare
variants have been associated with AF in families (14).
Taken together, these data provide a strong argument that
SNPs at the 4q25 locus confer AF risk by modulating
PITX2 function. However, studies relating 4q25 risk allele
genotypes to PITX2 expression in adult atrial samples have
provided conﬂicting results, and the mechanism whereby
4q25 SNPs act to generate an AF-prone substrate in
humans remains uncertain.
In this issue of the Journal, Lubitz et al. (15) add in
several important ways to our understanding of the role
of the 4q25 locus in mediating AF risk. First, they
demonstrate that multiple SNPs within the locus actually
confer risk independent of one another. One of these is
remarkably close, 7,000 base pairs, to the actual PITX2
gene, and thus adds to the indirect body of evidence that
the 4q25 locus acts by modulating PITX2 function. Sec-
ond, they build on their own previous report (16) to show
that combinations of independent SNPs at the 4q25 locus
contribute in an additive fashion to AF risk. Thus,
although the relative risk for any single allele identiﬁed
by GWAS is <2, this value can rise to 4 to 5 in a small
number of individuals with combinations of risk alleles.
This resonates with the idea that combinations of risk
alleles may be especially important in generating many
human phenotypes; for example, our group has shown
that 4q25 risk alleles are likely modulators of the pene-
trance of rare variants in families (17). Third, they report
that the SNPs conferring AF risk in Caucasian pop-
ulations are now replicated in a large Japanese cohort.
This is not a surprise, given that the original 2007 report
included a small number of individuals of Asian ancestry.
Further, although it seems improbable that the funda-
mental pathways to AF (or most other diseases) will vary
by ancestry, it is entirely possible that the speciﬁc risk
variants will (18). Interestingly, individuals of African
origin display an apparently reduced incidence of AF,
despite an equivalent or greater burden of traditional risk
factors such hypertension and diabetes (19). One report
suggests that AF risk in African Americans is determined
by the extent of global genetic admixture with Caucasian
populations (20), and it remains an interesting and
important unknown whether African-American subjects
harbor protective alleles.
The next steps. The initial use of large-scale population
approaches such as GWAS to study complex traits in anunbiased fashion was associated with hype suggesting that
we would soon see genomic markers conferring very high
risk. This expectation has not been met and is unrealistic for
several reasons. First, complex traits are complex, so the
expectation that a genetic test will deﬁnitively rule in or rule
out a complex trait is unrealistic: genetics shades the odds for
common disease. Second, GWAS attempts to identify as-
sociations between common genetic variants and disease,
and the notion that common variants could confer high risk,
at least for diseases that could occur at reproductive ages,
runs counter to the concepts of conventional evolutionary
pressure: such high-risk common alleles would not persist in
the population. Interesting exceptions are in pharmacoge-
nomics (where there has been no evolutionary pressure)
(21,22) or in diseases presenting after reproduction, such as
age-related macular degeneration (23). Indeed, one reason
GWAS has been so successful in identifying robust signals
for AF may be that the arrhythmia largely occurs in the post-
reproductive period.
A failure to deliver on initial hype has created skeptics
around the use of genomic information in clinical practice.
GWAS for AF highlights the way in which these data will
inform future practice in many diseases. No one would have
guessed that variation in a developmental pathway would
confer risk for AF. Although many details remain to be
worked out, including whether, in fact, PITX2 is the “culprit”
gene, there is every reason to hope that understanding the
mechanism whereby these alleles so consistently confer risk
will then inform development of targeted and effective
therapies for treatment and, more importantly, for prevention
of the arrhythmia. Biomarkers based on this new under-
standing could be deployed to identify patients at very high
risk of arrhythmia before development of the ﬁrst episode.
New drugs can and should be developed to treat and prevent
the arrhythmia. A new biology, relating the risk alleles to
other emerging factors, such as atrial ﬁbrosis, should emerge.
Thus, AF genomics has every potential to inform not only
treatment of AF, but also its prevention. Focusing on using
fundamental new knowledge to develop ways to prevent the
onset of the arrhythmia in the 63-year-old physician does not
seem completely unrealistic, and holds out the hope that
AF will not become the epidemic that many have predicted
as the population ages (19).
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